primary angle-closure glaucoma
Conditions
Interventions
Group1:phacoemulsificaiton and IOL and goniosynechialysis implantation
Group1:ab interno trabeculectomy
Sponsors
Changsha Aier Eye Hospital
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Part I inclusion criteria 1. Aged >= 40 years; 2. Diagnosis of Primary Angle Closure or primary angle closure glaucoma; 3. More than or equal to 180 degrees of PAS (not necessarily contiguous); 4. IOP > 21 mmHg if untreated or 21 mmHg if untreated or <= 21 mmHg on topical medication; 3. Written informed consent.
Exclusion criteria
Exclusion criteria: Part I exclusion criteria were: 1. Previous intraocular surgery (except laser iridotomy was allowed) and previous refractive corneal surgery; 2. Previous tramatic damage of aqueous humor drainage system in the anterior chamber (such as recession of chamber Angle); 3. Evidence of moderate non-proliferative diabetic retinopathy, neovascularization, or rubeosis iridis, uveitis, retinitis pigmentosa, occlusion of retinal vessels and dislocation of the lens; 4. Serious ocular surface diseases which affect the use of gonioscope; 5. Chronic use of topical or systemic steroids and allergic to sulfanilamide; 6. Advanced glaucoma with severe visual field (VF) defect, defined as visual field deficit threatening fixation; 7. Surgical complications including: no IOL implantation, rupture of posterior capsule and anterior vitrectomy; 8. Patients were unable to complete the follow-up for 6 months; Part II exclusion criteria were: 1. Previous intraocular surgery (except laser iridotomy and trabeculectomy were allowed) and previous refractive corneal surgery; 2. Previous tramatic damage of aqueous humor drainage system in the anterior chamber (such as recession of chamber Angle); 3. Evidence of moderate non-proliferative diabetic retinopathy, neovascularization, or rubeosis iridis ,uveitis, retinitis pigmentosa, occlusion of retinal vessels and dislocation of the lens; 4. Serious ocular surface diseases which affect the use of gonioscope; 5. Anticoagulants, INR > 3.0 within a week before surgery; 6. Chronic use of topical or systemic steroids and allergic to sulfanilamide; 7. Patients were unable to complete the follow-up for at least 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intraocular pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| the number of anti-glaucoma eye drop;visual acuity;complications during follow up period;ocular parameters of anterior chamber; | — |
Countries
China
Contacts
Public ContactLin Ding
Aier School of Opthalmology, Central South University
Outcome results
None listed